Tag Archives: ProciseDx

November 2019—ProciseDx received the CE mark for its Pro-ciseDx point-of-care diagnostic platform. The company will develop and commercialize near-patient, two- to five-minute tests to precisely quantify diagnostic and treatment
 monitoring markers for inflammatory and autoimmune diseases, such as celiac, and metabolic syndromes, including diabetes and prediabetes.